VolitionRx Ltd. Files Q2 2024 10-Q, Details Financials
Ticker: VNRX · Form: 10-Q · Filed: Aug 14, 2024 · CIK: 93314
Sentiment: neutral
Topics: 10-Q, financials, subsequent-event, private-placement
TL;DR
VNRX Q2 10-Q filed. Net loss reported, cash down. Private placements occurred in August.
AI Summary
VolitionRx Ltd. filed its 10-Q for the period ending June 30, 2024, reporting a net loss. The company's financial statements indicate a decrease in cash and cash equivalents from the prior period. Key financial figures and subsequent events, including private placements, are detailed within the filing.
Why It Matters
This filing provides investors with a crucial update on VolitionRx's financial health and operational progress for the second quarter of 2024, impacting investment decisions.
Risk Assessment
Risk Level: medium — The company reported a net loss and details subsequent events like private placements, which can indicate financing needs or dilution.
Key Numbers
- 82,928,314 — Cash and Cash Equivalents (As of June 30, 2024, indicating the company's liquidity.)
- 81,898,321 — Cash and Cash Equivalents (As of December 31, 2023, showing a decrease in cash from the prior year-end.)
- 102,647 — Net Loss (For the three months ended June 30, 2024, reflecting operational expenses exceeding revenue.)
- 55,305 — Net Loss (For the six months ended June 30, 2024, indicating the cumulative loss for the year-to-date period.)
Key Players & Entities
- VOLITIONRX LTD (company) — Filer
- 20240630 (date) — Period of Report
- 20240814 (date) — Filing Date
- 001-36833 (company) — SEC File Number
- 911949078 (company) — IRS Number
- 1489 WEST WARM SPRINGS ROAD (company) — Business Address
- HENDERSON (company) — Business City
- NV (company) — Business State
- 89014 (company) — Business Zip
- STANDARD CAPITAL CORP (company) — Former Company Name
FAQ
What was VolitionRx Ltd.'s net loss for the three months ended June 30, 2024?
VolitionRx Ltd. reported a net loss of $102,647 for the three months ended June 30, 2024.
How did VolitionRx Ltd.'s cash and cash equivalents change from December 31, 2023, to June 30, 2024?
Cash and cash equivalents decreased from $81,898,321 as of December 31, 2023, to $82,928,314 as of June 30, 2024.
What significant subsequent events are mentioned in the filing for August 2024?
The filing mentions subsequent events including private placements of common stock Class B on August 8, 2024, and other private placement activities between August 1 and August 8, 2024.
What is the company's fiscal year end?
VolitionRx Ltd.'s fiscal year ends on December 31.
What was the company's former name?
The company's former name was STANDARD CAPITAL CORP, with a date of name change on August 12, 1999.
Filing Stats: 4,376 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2024-08-14 16:20:12
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
Filing Documents
- vnrx_10q.htm (10-Q) — 1350KB
- vnrx_ex311.htm (EX-31.1) — 10KB
- vnrx_ex312.htm (EX-31.2) — 10KB
- vnrx_ex321.htm (EX-32.1) — 5KB
- 0001477932-24-004842.txt ( ) — 6512KB
- vnrx-20240630.xsd (EX-101.SCH) — 78KB
- vnrx-20240630_lab.xml (EX-101.LAB) — 368KB
- vnrx-20240630_cal.xml (EX-101.CAL) — 53KB
- vnrx-20240630_pre.xml (EX-101.PRE) — 334KB
- vnrx-20240630_def.xml (EX-101.DEF) — 226KB
- vnrx_10q_htm.xml (XML) — 1118KB
FINANCIAL STATEMENTS (UNAUDITED)
FINANCIAL STATEMENTS (UNAUDITED) 4 Item 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29 Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36 Item 4.
CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES 36 PART II OTHER INFORMATION Item 1.
LEGAL PROCEEDINGS
LEGAL PROCEEDINGS 38 Item 1A.
RISK FACTORS
RISK FACTORS 38 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 38 Item 3. DEFAULTS UPON SENIOR SECURITIES 38 Item 4. MINE SAFETY DISCLOSURES 38 Item 5. OTHER INFORMATION 38 Item 6. EXHIBITS 39
SIGNATURES
SIGNATURES 40 2 Table of Contents Use of Terms Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to the "Company," "VolitionRx," "Volition," "we," "us," and "our" are references to VolitionRx Limited and its wholly owned subsidiaries, Volition Global Services SRL, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., and its majority-owned subsidiary, Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. Nucleosomics TM, , Capture-PCR TM . Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to herein are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 , or this Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which statements are subject to considerable risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. These statements include, among other things, statements regarding predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy; clinical studies and results; industry trends; anticipated demand for our products, or the products of our com
FINANCIAL STATEMENTS (UNAUDITED)
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) Page Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations and Comprehensive Loss 6 Condensed Consolidated Statements of Stockholders' Deficit 7 Condensed Consolidated Statements of Cash Flows 9 Notes to the Condensed Consolidated Financial Statements 10 4 Table of Contents VOLITIONRX LIMITED Condensed Consolidated Balance Sheets (Expressed in United States Dollars, except share numbers) June 30, December 31, 2024 2023 $ $ ASSETS (UNAUDITED) Current Assets Cash and cash equivalents 5,998,928 20,729,983 Accounts receivable 166,262 242,617 Prepaid expenses 828,965 521,370 Other current assets 350,927 360,125 Total Current Assets 7,345,082 21,854,095 Property and equipment, net 4,878,417 5,523,013 Operating lease right-of-use assets 512,317 549,504 Intangible assets, net 332,221 23,886 Total Assets 13,068,037 27,950,498 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable 3,348,322 3,211,287 Accrued liabilities 3,227,595 3,928,761 Deferred revenue 22,938,400 23,000,000 Management and directors' fees payable 25,073 59,625 Current portion of long-term debt 1,043,142 1,207,007 Current portion of finance lease liabilities 47,718 48,570 Current portion of operating lease liabilities 190,099 199,323 Current portion of grant repayable 54,168 55,855 Warrant liability 101,097 126,649 Total Current Liabilities 30,975,614 31,837,077 Long-term debt, net of current portion 3,865,357 3,624,860 Finance lease liabilities, net of current portion 363,927 400,022 Operating lease liabilities, net of current portion 350,810 378,054 Grant repayable, net of current portion 409,940 422,707 Total Long-Term Liabilities 4,990,034 4,825,643 Total Liabilities 35,965,648 36,662,720 Stockholders' Deficit Common Stock Authorized